article thumbnail

An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

Bio Pharma Dive

Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.

DNA 267
article thumbnail

Breaking Barriers in Solid Tumor Research: Precision Medicine & Strategic Operations

Worldwide Clinical Trials

However, the emergence of precision medicine is revolutionizing the way we approach these tumors, offering new hope and innovative solutions. Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention? Request early access here for the white paper.

Medicine 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking the Future of Personalized Medicine: Blood vs. Buccal Swab in Pharmacogenomics Testing

Worldwide Clinical Trials

At Worldwide, our recent study delved into the intricacies of PGx, comparing two common methods of DNA sample collection: buccal swabs and blood samples. These results are largely due to the higher cell density in blood, which includes DNA-rich white blood cells. for buccal swabs and 93.2% for blood samples.

Medicine 182
article thumbnail

A startup emerges with $125M and plans to edit the epigenome

Bio Pharma Dive

Chroma Medicine's launch is the latest step in a decadeslong quest by drugmakers to capitalize on research into epigenetics, a way of controlling gene expression without altering DNA.

article thumbnail

Intellia, ReCode partner on genetic medicines for cystic fibrosis

Bio Pharma Dive

The partnership will use Intellia's "DNA writing” technology, and initially focus on people with the lung disease who have limited or no available treatment options.

Genetics 177
article thumbnail

Modernizing cell culture processes for the next wave of genomic medicine

Pharmaceutical Technology

The field of genomic medicine has reached a true turning point. In June 2022, the European Medicines Agency approved an adeno-associated viral (AAV) vector-based therapy for adults with Hemophilia A, making the treatment available to an estimated 3,200 eligible patients. [1] CEVEC became part of Cytiva in October 2022.

Genome 244
article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130